Simvastatin in Uveitis
Open-label Randomized Study of Efficacy and Safety of Simvastatin in Uveitis
StatusCompleted No Results Posted
The study evaluates anti-inflammatory effects and safety of simvastatin in non-infectious uveitis.
3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors (statins) have been shown to reduce local and systemic inflammation in animal models of various autoimmune disorders including uveitis. In this open-label, randomized study clinical efficacy and tolerability of simvastatin 40 mg/day for 8 weeks is evaluated.
40 mg simvastatin per day for 2 months in addition to conventional treatment of uveitis
conventional treatment of uveitis
Inclusion Criteria: - diagnosis of active non-infectious uveitis Exclusion Criteria: serious liver or kidney disease increased transaminase levels of >1.5 ULN planned or active pregnancy use of fibrates, nicotinic acid, cyclosporine A, antifungal drugs, macrolide antibiotics, verapamil, and grapefruit juice (>1 L/day).